Recombinant COVID-19 protein vaccine (Yzy Biopharma)

新冠重组蛋白疫苗（友芝友生物）

Report date: 2022/04/18 11:17:40

Base Information

Drug NameRecombinant COVID-19 protein vaccine (Yzy Biopharma)
Drug Alias NameY2019
ClassificationVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuhan Yzy Biopharma Co LtdWuhan Institute Of Virology, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Yzy Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A